| Field | Specification |
|---|---|
| Target | |
| Alternative names | Integrin alpha-V; Vitronectin receptor; Vitronectin receptor subunit alpha; CD antigen CD51; ITGAV; MSK8; VNRA; VTNR |
| UniProt # | |
| Host | |
| Clone | |
| Clonality | |
| Isotype | |
| Reactivity | |
| Applications | |
| Immunogen | E.coli-derived human Integrin alpha V/ITGAV recombinant protein (Position: H732-D970). |
| Molecular weight | |
| Purification | |
| Reconstitution | |
| Cellular localization | |
| Concentration | |
| Form | Lyophilized |
| Storage | |
| Catalog no. (Mfr.) | |
| Main SKU |
Product Overview
Clone 8B10H2 is a mouse monoclonal antibody that recognizes integrin alpha-V (gene ITGAV) in human samples and is validated for Western blot, IHC and ICC/IF. The predicted molecular weight is 116.0 kDa, and the supplier reports an observed band at about 130 kDa.
Integrin alpha-V (ITGAV, CD51) pairs with several beta subunits (β1, β3, β5, β6, β8) to form receptors that recognize the RGD motif in vitronectin, fibronectin, osteopontin and other matrix proteins. Alpha-V integrins also activate latent TGF-β, and they are studied in angiogenesis, fibrosis and tumor biology.
| Target | Integrin alpha-V (gene ITGAV; UniProt P06756, human) |
|---|---|
| Clone | 8B10H2 |
| Host / Clonality / Isotype | Mouse / Monoclonal / Mouse IgG2b |
| Reactivity | Human |
| Form | Lyophilized |
| Formulation | Per vial: 4 mg trehalose; 0.9 mg NaCl; 0.2 mg Na2HPO4 |
| Calculated MW | 116.0 kDa |
| Observed MW | 130 kDa |
| Storage | As supplied: −20 °C for up to 12 months from receipt. After reconstitution: 4 °C for up to 1 month, or aliquot and keep at −20 °C for up to 6 months. Avoid repeated freeze–thaw cycles. |
Validated Applications
| Western blot | 0.25–0.5 µg/mL (Human) |
|---|---|
| IHC (paraffin sections) | 2–5 µg/mL (Human) |
| Immunocytochemistry / Immunofluorescence | 5 µg/mL (Human) |
Samples with a confirmed band (WB): human MCF-7 cells, human A549 cells, human RT4 cells, human HepG2 cells, human HeLa cells, human SiHa cells, human A431 cells.
Recommended loading (WB): 20–40 µg of total protein per lane.
Conditions in the example images (WB): 5–20% gradient SDS-PAGE under reducing conditions, 30 µg lysate per lane, transfer to nitrocellulose membrane, blocking in 5% non-fat milk, primary antibody at 0.5 µg/mL overnight at 4 °C, HRP-conjugated secondary antibody at 1:10000, ECL detection.
Samples with confirmed staining (IHC): human placenta tissue, human esophageal squamous carcinoma tissue.
Recommended antigen retrieval: heat-mediated, in TE buffer (pH 9.0); citrate buffer (pH 6.0) can be used instead.
Conditions in the example images (IHC): heat-mediated antigen retrieval in EDTA buffer (pH 8.0).
Samples with confirmed staining (ICC/IF): A549 cells.
Immunogen
Recombinant human Integrin alpha V/ITGAV fragment (His732–Asp970), expressed in E. coli.
Reactivity Notes
The supplier lists reactivity with human. UniProt places integrin alpha-V in the cell membrane and cell junction. The samples tested by the supplier (listed above) are a practical starting point for positive controls.
Safety
Customization & Add-ons: Can’t find the antibody you need—or require a custom format for your assay? We can help you source the best match or support custom antibody solutions for diverse research needs, including species and isotype selection, conjugations and labeling (e.g., HRP/AP, biotin, fluorophores), purification grade options (Protein A/G, affinity purified), formulation preferences (buffer selection, carrier-free, glycerol-free), custom concentrations and aliquoting, low-endotoxin options for cell-based work, and application-focused QC/validation support (project dependent). Click Talk to a Scientist to submit a request, email us at support@biohippo.com, or explore our Research Services for additional support—our team will follow up with feasibility details and next steps.
Lixiang Liu et al. (2019) The impact of chronic endometritis on endometrial fibrosis and reproductive prognosis in patients with moderate and severe intrauterine adhesions: a prospective cohort study. Fertility and Sterility. 10.1016/j.fertnstert.2019.01.006
